

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C.371**ATTORNEY'S DOCKET NUMBER  
**HKZ-034CPUS**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**09/830221**INTERNATIONAL APPLICATION  
**PCT/US99/24769**INTERNATIONAL FILING DATE  
**22 October 1999 (22.10.99)**PRIORITY DATE CLAIMED  
**23 October 1998 (23.10.98)**

## TITLE OF INVENTION

**CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID  
IMMUNIZATION OF CATS**

## APPLICANT(S) FOR DO/EO/US

**Joel R. HAYNES, Ramani S. WONDERLING; and Dan T. STINCHCOMB**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C.371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- a. ☐ is attached hereto (required only if not communicated by the International Bureau) (**37 sheets**);
- b. ☒ has been communicated by the International Bureau.
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- a. ☐ are attached hereto (required only if not communicated by the International Bureau).
- b. ☐ have been communicated by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unexecuted) (**4 sheets**)
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13. ☒ A **FIRST** preliminary amendment (**2 sheets**);
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: **Transmittal Letter (2 sheets in duplicate); PCT International Published Application (WO 00/24428) (38 sheets); PCT International Published Application WO 00/24428 with Search Report (6 sheets); PCT Notification Concerning Submission of Priority Documents (PCT/IB/304) (1 sheet); PCT Notice Informing the Applicant of the Communication of the International Application to the Designated Offices (PCT/IB/308) (1 sheet); PCT Written Opinion (8 sheets) and cited references; and PCT International Preliminary Examination Report (10 sheets); check in the amount of \$981.00 based on small entity status; Certificate of Express Mailing and Return Postcard.**

09/830221

PCT/US99/24769

HKZ-034CPUS

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) .(a/o November 1, 2000):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO.....\$1000

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO .....\$860

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.455(a)(2)) paid to USPTO .....\$710

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	59-20 =	39	X \$18.00
Independent claims	3-3 =	0	X \$80.00

\$ 702.00

\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable)

+ 270.00

\$ 270.00

**TOTAL OF ABOVE CALCULATIONS =**

\$1,962.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2.

\$ 981.00

**SUBTOTAL =**

\$ 981.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$ 981.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

**TOTAL FEES ENCLOSED =**

\$ 981.00

Amount to be:  
refunded

\$

charged

\$

- a. ☒ A check in the amount of \$ 981.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit  
any overpayment to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**Elizabeth A. Hanley, Esq.**  
**LAHIVE & COCKFIELD, LLP**  
**28 State Street**  
**Boston, Massachusetts 02109**  
**United States of America**  
**(617)227-7400**  
**Date: 23 April 2001**

SIGNATURE

NAME

41,710

REGISTRATION NUMBER

09/830221

JC18 Rec'd PCT/PTO 23 APR 2001  
(Atty. Docket No.: HKZ-034CPUS)

**IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)**  
**(National Phase of International App.: PCT/US99/24769, Publication No. WO 00/24428)**

In re the  
application of: **Joel R. HAYNES, et al.**

International Application No.: **PCT/US99/24769**  
(Publication No. WO 00/24428)

International Filing Date: **22 October 1999**

U.S. Serial No.: **Not Yet Assigned**

Filed: **Herewith**

**For: CATIONIC LIPID-MEDIATED  
ENHANCEMENT OF NUCLEIC ACID  
IMMUNIZATION OF CATS**

Attorney Docket No.: **HKZ-034CPUS**

**BOX PCT**

Commissioner for Patents  
Washington, DC 20231

**CERTIFICATION UNDER 37 CFR 1.10**

Date of Deposit: April 23, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Washington, DC 20231.

Viriato G. Cardoso  
Name of Person Mailing Paper

  
Signature of Person Mailing Paper

**FIRST PRELIMINARY AMENDMENT**

Dear Sir:

Preliminary to examination of the above-referenced patent application, please amend the enclosed above-titled International patent application as follows.

In the Claims:

Please cancel claim 19 without prejudice.

**REMARKS**


Claims 1-27 were pending in the above-identified International application. Claim 19 has been canceled to reduce the number of claims and to remove multiple dependencies. Accordingly, claims 1-18 and 20-27 are currently pending in this application. The foregoing amendment introduces no new matter.

Entry of the foregoing First Preliminary Amendment is respectfully in order and requested.

If there are any questions regarding the amendments to the application, we invite the Examiner to call Applicants' representative at the telephone number below.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

  
Jeanne M. DiGorgio  
Registration No. 41,710  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
Tel: 617-227-7400  
Fax: 617-742-4214

Date: April 23, 2001

2001 APR 23 10 43 AM

CATIONIC LIPID-MEDIATED ENHANCEMENT OF  
NUCLEIC ACID IMMUNIZATION OF CATS

FIELD OF THE INVENTION

The present invention relates to a method to introduce a nucleic acid molecule  
5 into a felid by administration of a nucleic acid molecule-cationic lipid complex  
composition. In particular, the present invention relates to the parenteral administration  
of a nucleic acid molecule-cationic lipid complex to elicit and/or enhance an immune  
response to the protein encoded by the administered nucleic acid molecule.

BACKGROUND OF THE INVENTION

10 Introduction of DNA into an animal for the purpose of eliciting an immune  
response is often referred to as DNA vaccination. DNA vaccination represents a means  
of expressing an antigen *in vivo* for the generation of humoral and cellular immune  
responses. DNA vaccines employ genes encoding antigens, rather than using the  
proteins themselves, to induce immune responses. The DNA, upon administration to the  
15 host, is transcribed and translated *in vivo* to produce an antigen. Processing and  
presentation of the antigen stimulates the animal's immune system to elicit a humoral  
and/or cellular response to the antigen. This immune response can potentially confer  
protective immunity to the animal.

20 DNA vaccines appear to have advantages over protein antigen-based vaccines,  
standard "killed" pathogen vaccines, live, attenuated vaccines, and recombinant viral  
vector vaccines. For example, DNA vaccines appear to be more effective in producing  
an antigen with a properly folded, native three-dimensional conformation and in  
generating a cellular immune response than are protein antigens. DNA vaccines also do  
25 not exhibit at least some of the safety problems of killed, live or virally-vectored  
vaccines. For example, a killed virus preparation may contain residual live viruses or  
may need to be mixed with reactogenic adjuvants, such as those associated with vaccine-  
related fibrosarcomas in cats, in order to stimulate an effective immune response. An  
attenuated virus may mutate and revert to a pathogenic phenotype. Viral vector vaccines  
30 genetically engineered to express a gene encoding the desired antigen may stimulate the  
production of antibodies that react with the virus as well; such antibodies may render  
futile any further attempt to use that virus as a vector, even with a different gene insert.

In contrast, DNA vaccines apparently are non-reactogenic and, if they elicit an immune response, that response is targeted against the antigen of choice.

DNA vaccines typically include a bacterial plasmid, a strong viral promoter, the gene of interest, and a polyadenylation/transcriptional termination sequence. The  
5 plasmid is typically grown in bacteria, purified, dissolved in a saline solution, and then simply injected into an animal. Current understanding of how to use DNA vaccines to generate an effective immune response, however, is not complete. Most of our understanding of the mechanisms of DNA vaccine action is derived from rodent studies. In mice, bone marrow-derived antigen-presenting cells have been shown to induce  
10 cytotoxic T lymphocyte responses following intramuscular inoculation of naked plasmid DNA. In some cases, DNA vaccination has also been shown to stimulate antigen-specific antibodies, some of which may be neutralizing antibodies. DNA vaccines have also been administered to large animals, albeit with varying degrees of success. While there are some clear examples of DNA vaccine efficacy in large animals, other studies  
15 cite relatively weak responses, requirement for large amounts of DNA, or the need for multiple immunizations. As such, it is apparent that further technology development is required to maximize DNA vaccine efficacy in humans and large animals.

Immune responses to DNA vaccination appear to vary according to the vehicle used with the DNA vaccine, the antigen expressed by the DNA vaccine, the route of  
20 administration, and the species of mammal into which the DNA vaccine is injected. Investigators have used different vehicles and/or genes encoding cytokines and other stimulatory molecules in an attempt to enhance the immune response to the antigens encoded by DNA vaccines with mixed success. Although cationic lipids have been used to deliver nucleic acids to cells *in vitro* and *in vivo*, there is no consensus in the literature  
25 about whether cationic lipids reproducibly enhance the immunogenicity of DNA vaccines. Gregoriadis et al., 1997, FEBS Letters 402, 107, reported that intramuscular (I.M.) injection of DNA encoding HBsA "entrapped" in cationic liposomes into mice elicited an enhanced immune response compared to I.M. injection of "naked" DNA encoding HBsA, whereas DNA encoding HBsA merely "complexed" with cationic lipid  
30 generated a reduced immune response compared to "naked" DNA. Ishii et al., 1997, AIDS Research and Human Retroviruses 13, 1421-1424, demonstrated enhanced

immune responses to V3 peptide following I.M., intraperitoneal (I.P.), intradermal (I.D.), intranasal (I.N.) or subcutaneous (S.Q.) administration to mice.

Other investigators, in contrast, found no enhancement of immune responses when cationic lipids were used as a vehicle for DNA vaccines in mice. For example, 5 Davis, et al., 1997, Vaccine 15, 849, found that DNA vaccines encoding the Hepatitis B surface antigen formulated with varying amounts of cationic lipids performed no better than DNA alone in inducing a humoral response in mice. Gramzinski, et al., 1998, Molecular Medicine 4, 109, reported that Aotus monkeys administered DNA vaccines encoding HBsA either with or without cationic lipids (CELLFECTIN®, 10:1 10 DNA:lipid) by I.M. injection did not seroconvert. Clearly, there is no consensus regarding whether cationic lipids reproducibly act to elicit or enhance immune responses to DNA vaccines.

There also appears to be a high degree of variability of the efficacy of DNA vaccines between different routes of administration. Ishii et al, *ibid.*, for example, found 15 in mice that I.M. and I.N. administration of DNA vaccines generated approximately equivalent immune responses, but that I.P. administration was less effective, and that I.D. and S.Q. administration routes were even less effective. Ishii et al, *ibid.*, found these differences to be consistent regardless of whether DNA was used alone or formulated with cationic lipids. Yokoyama et al, 1996, FEMS Immuno Med Microbio 20 14, 221-230, showed that I.V. administration of a DNA vaccine generated a better immune response than I.M. administration of the same vaccine in mice.

Taken together, these data indicate that there is a high degree of variability in the effectiveness of DNA vaccines and in the ability of cationic lipids to enhance the effectiveness of DNA vaccines both within and between species and routes of 25 administration.

There are a number of diseases in cats which lead to significant morbidity and mortality. It would be desirable to provide novel and safe vaccines that would confer protective immunity to these diseases. That there is still a need for such vaccines is underscored not only by the association of some feline vaccines with the development of 30 fibrosarcomas but also by the finding that I.M. administration of naked DNA encoding either human growth hormone (hGH) or rabies virus glycoprotein G into domestic cats

resulted in incomplete seroconversion, even after two immunizations (Osorio et al, 1999, Vaccine, in press). These results indicate that parenteral naked DNA vaccination efficacy in cats is inferior to results obtained in mice, and that the efficacy achieved using naked DNA in cats is not sufficient to protect cats from disease. Thus, there  
5 remains a need to provide a method to elicit and to enhance the immune response to antigen encoded by DNA vaccines in cats.

#### SUMMARY OF THE INVENTION

The present invention relates to a method to elicit an immune response to an antigen in a felid. This method includes the step of parenterally administering to the  
10 felid a composition comprising a nucleic acid molecule encoding the antigen in which the nucleic acid molecule is complexed with a cationic lipid. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid molecule to a felid. This method comprises parenterally administering to  
15 the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.

#### DETAILED DESCRIPTION

The present invention relates to a method to elicit an immune response to an antigen in a felid. The method includes the step of parenterally administering to the felid  
20 a composition comprising a nucleic acid molecule encoding the antigen in which the nucleic acid molecule is complexed with a cationic lipid. The ability of such a method to elicit an immune response to the antigen encoded by the nucleic acid molecule is new and surprising. Until recently, the general perception of those skilled in the art was that cationic lipids did not enhance the ability of a nucleic acid molecule to elicit an immune  
25 response, compared to, for example, delivery of a naked, or unformulated, nucleic acid molecule (i.e., a nucleic acid molecule that is not complexed with, for example, a lipid or other transfection-facilitating agents). Recent studies, cited above, have provided conflicting results: although two studies in mice demonstrated that cationic lipids enhanced the ability of DNA to elicit an immune response, a third study concluded that  
30 cationic lipid-complexed DNA was no better than naked DNA at eliciting an immune response. In addition, monkeys administered a nucleic acid molecule-cationic lipid

complex did not exhibit seroconversion to the antigen encoded by the nucleic acid molecule. Furthermore, the inventors have demonstrated that while parenteral administration to a felid of a nucleic acid molecule complexed with a cationic lipid results in the felid successfully seroconverting in response to the antigen encoded by the nucleic acid molecule, intranasal administration of such a composition did not result in seroconversion. Thus, the ability to demonstrate seroconversion in cats parenterally administered a nucleic acid molecule complexed with a cationic lipid is completely unpredictable based on previous studies and, as such, is inventive.

One embodiment of the present invention is the use of a composition comprising a nucleic acid molecule encoding an antigen complexed with a cationic lipid to elicit an immune response in a felid. It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, a nucleic acid molecule, an antigen, and a cationic lipid refers to one or more nucleic acid molecules, antigens, and cationic lipids, respectively; or to at least one nucleic acid molecule, antigen, and cationic lipid, respectively. As such, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably. Furthermore, a member of a group that is "selected from the group consisting of" refers to one or more of members of that group, including combinations thereof.

A nucleic acid molecule of the present invention also referred to herein as a nucleic acid, can be DNA or RNA. In one embodiment, a nucleic acid molecule encodes an antigen that elicits an immune response in a felid. As such, a nucleic acid molecule can simply be a molecule that encodes such an antigen, i.e., a coding region, or the nucleic acid molecule can comprise a coding region operatively linked to a regulatory sequence. As used herein, the phrase operatively linked refers to the joining of a coding region to one or more regulatory sequences such that the coding region is expressed using such regulatory sequence(s) in a felid. Examples of such regulatory sequences include transcription control sequences and translation control sequences that can be recognized by felid cellular mechanisms in order to effect transcription and translation of a coding region. Transcription control sequences are sequences that control the initiation, elongation, and termination of transcription (e.g., promoters,

enhancers, introns, polyA sites, terminators). Translation control sequences control the initiation, elongation and termination of translation. Additional regulatory sequences include signal sequences that effect secretion of a protein from a cell and a combination of a signal sequence and a transmembrane sequence (i.e., membrane anchoring domain) that causes a protein to be partially extracellular and partially retained in the membrane and/or cytoplasm. A preferred nucleic acid molecule of the present invention is a plasmid or viral genome that includes a coding region for the desired antigen operatively linked to strong eukaryotic regulatory sequences, including a strong promoter and strong transcription termination/polyadenylation sequences. A preferred plasmid can replicate in bacteria. Procedures by which such a nucleic acid molecule is produced are known to those skilled in the art, and are disclosed, for example, in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press. Appropriate plasmids are known in the art, and may include, but are not limited to, pUC19 and BLUESCRIPT®. A preferred plasmid is pUC19. Appropriate regulatory sequences are known to those skilled in the art. For example, a suitable promoter includes, but is not limited to the cytomegalovirus immediate early promoter (CMV IE) with or without intron A, a long terminal repeat (LTR) promoter from a retrovirus, or a strong cellular promoter such as  $\beta$ -actin, with CMV IE with intron A being preferred. Similarly, suitable transcription termination sequences include, but are not limited to, bovine growth hormone, SV40 virus or rabbit beta-globin polyadenylation sequences, with a bovine growth hormone sequence being preferred.

A suitable antigen is any antigen that effects an immune response, and as such includes allergens and autoantigens as well as other antigens. An antigen, as used herein, can refer to the full-length antigen or any portion thereof that is capable of eliciting an immune response. Preferred antigens are those that elicit an immune response that protects an animal from disease. Examples of such antigens include, but are not limited to, a protozoan parasite antigen, a helminth parasite antigen, an ectoparasite antigen, a fungal antigen, a bacterial antigen, and a viral antigen. Examples of viral antigens include, but are not limited to, antigens from adenoviruses, caliciviruses, coronaviruses, distemper viruses, hepatitis viruses, herpesviruses, immunodeficiency viruses, infectious peritonitis viruses, leukemia viruses, oncogenic

bacterial antigens include, but are not limited to, antigens from *Actinomyces*, *Bacillus*, *Bacteroides*, *Bordetella*, *Bartonella*, *Borrelia*, *Brucella*, *Campylobacter*,

- 5 *Capnocytophaga*, *Clostridium*, *Corynebacterium*, *Coxiella*, *Dermatophilus*,  
*Enterococcus*, *Ehrlichia*, *Escherichia*, *Francisella*, *Fusobacterium*, *Haemobartonella*,  
*Helicobacter*, *Klebsiella*, L-form bacteria, *Leptospira*, *Listeria*, *Mycobacteria*,  
*Mycoplasma*, *Neorickettsia*, *Nocardia*, *Pasteurella*, *Peptococcus*, *Peptostreptococcus*,  
10 *Proteus*, *Pseudomonas*, *Rickettsia*, *Rochalimaea*, *Salmonella*, *Shigella*, *Staphylococcus*,  
*Streptococcus*, and *Yersinia*. Examples of fungal antigens include, but are not limited  
to, antigens from *Absidia*, *Acremonium*, *Alternaria*, *Aspergillus*, *Basidiobolus*,  
*Bipolaris*, *Blastomyces*, *Candida*, *Chlamydia*, *Coccidioides*, *Conidiobolus*,  
*Cryptococcus*, *Curvalaria*, *Epidermophyton*, *Exophiala*, *Geotrichum*, *Histoplasma*,  
*Madurella*, *Malassezia*, *Microsporum*, *Moniliella*, *Mortierella*, *Mucor*, *Paecilomyces*,  
15 *Penicillium*, *Phialemonium*, *Phialophora*, *Prototheca*, *Pseudallescheria*,  
*Pseudomicrodochium*, *Pythium*, *Rhinosporidium*, *Rhizopus*, *Scolecobasidium*,  
*Sporothrix*, *Stemphylium*, *Trichophyton*, *Trichosporon*, and *Xylohypha*. Example of  
protozoan and helminth parasite antigens include, but are not limited to, antigens from  
*Babesia*, *Balantidium*, *Besnoitia*, *Cryptosporidium*, *Eimeria*, *Encephalitozoon*,  
20 *Entamoeba*, *Giardia*, *Hammondia*, *Hepatozoon*, *Isospora*, *Leishmania*, *Microsporidia*,  
*Neospora*, *Nosema*, *Pentatrichomonas*, *Plasmodium*, *Pneumocystis*, *Sarcocystis*,  
*Schistosoma*, *Theileria*, *Toxoplasma*, and *Trypanosoma*, *Acanthocheilonema*,  
*Aelurostrongylus*, *Ancylostoma*, *Angiostrongylus*, *Ascaris*, *Brugia*, *Bunostomum*,  
*Capillaria*, *Chabertia*, *Cooperia*, *Crenosoma*, *Dictyocaulus*, *Dioctophyme*,  
25 *Dipetalonema*, *Diphyllobothrium*, *Diplydium*, *Dirofilaria*, *Dracunculus*, *Enterobius*,  
*Filaroides*, *Haemonchus*, *Lagochilascaris*, *Loa*, *Mansonella*, *Muellerius*, *Nanophyetus*,  
*Necator*, *Nematodirus*, *Oesophagostomum*, *Onchocerca*, *Opisthorchis*, *Ostertagia*,  
*Parafilaria*, *Paragonimus*, *Parascaris*, *Physaloptera*, *Protostrongylus*. *Setaria*,  
*Spirocerca*, *Spirometra*, *Stephanofilaria*, *Strongyloides*, *Strongylus*, *Thelazia*,  
30 *Toxascaris*, *Toxocara*, *Trichinella*, *Trichostrongylus*, *Trichuris*. *Uncinaria*, and  
*Wuchereria*. Examples of ectoparasite antigens include, but are not limited to, antigens

(including protective antigens as well as allergens) from fleas; ticks, including hard ticks and soft ticks; flies, such as midges, mosquitos, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, stable flies, myiasis-causing flies and biting gnats; ants; spiders, lice; mites; and true bugs, such as bed bugs and kissing bugs. Additional  
5 examples of suitable allergens include food, grass, weed, tree pollen, other animal and other plant allergens.

Preferred antigens include, but are not limited to, a calicivirus antigen, a coronavirus antigen, a herpesvirus antigen, an immunodeficiency virus antigen, an infectious peritonitis virus antigen, a leukemia virus antigen, a panleukopenia virus  
10 antigen, a parvovirus antigen, a rabies virus antigen, a *Bartonella* antigen, a *Yersinia* antigen, a *Dirofilaria* antigen, a *Toxoplasma* antigen, a tumor antigen, a flea antigen, a flea allergen, a midge antigen, a midge allergen, a mite antigen, a mite allergen, a ragweed allergen, a ryegrass allergen, a cat allergen, a dog allergen, a Bermuda grass allergen, a Johnson grass allergen, or a Japanese cedar pollen allergen. Particularly  
15 preferred antigens include a rabies virus glycoprotein G antigen; heartworm PLA2, P39, P4, P22U, Gp29, astacin, cysteine protease, macrophage migration inhibitory factor, venom allergen, TPX-1, TPX-2, transglutaminase, ankyrin, asparaginase, calreticulin, cuticulin, and aromatic amino acid decarboxylase antigens; flea serine protease, cysteine protease, aminopeptidase, serpin, carboxylesterase, juvenile hormone esterase, chitinase,  
20 epoxide hydrolase, ecdysone, ecdysone receptor, and ultraspiracle protein antigens; flea salivary antigens; *Yersinia* F1 and V antigens; and *Toxoplasma gondii* antigens such as those disclosed in PCT Patent Publication No. WO 99/32633, published July 1, 1999, by Milhausen et al. Additional examples of suitable and preferred allergens are disclosed in  
25 U.S. Patent No. 5,945,294, issued August 31, 1999, by Frank et al. (US 5,945,294); U.S. Patent No. 5,958,880, issued September 28, 1999, by Frank et al. (US 5,958,880); PCT Patent Publication No. WO 98/45707, published October 15, 1998, by Frank et al. (WO 98/45707); and PCT Patent Publication No. WO 99/38974, published August 5, 1999, by Weber et al. (WO 99/38974).

One embodiment of the present invention is a composition comprising a nucleic  
30 acid molecule-cationic lipid complex that further comprises a heterologous nucleic acid molecule encoding an immunomodulator. Such an immunomodulator-encoding nucleic

acid molecule can be contained within the same nucleic acid molecule encoding the antigen of the present invention, or can exist as a separate nucleic acid molecule, which can be on the same or separate plasmid or viral genome. The present invention also includes Suitable immunomodulators include compounds that enhance certain immune responses as well as compounds that suppress certain immune responses. Compounds that enhance the immune response include compounds that preferentially enhance humoral immunity as well as compounds that preferentially enhance cell-mediated immunity. Suitable compounds can be selected depending on the desired outcome. Suitable immunomodulators include, but are not limited to, cytokines, chemokines, superantigens, co-stimulatory molecules, adhesion molecules, and other immunomodulators as well as compounds that induce the production of such immunomodulators. Examples of such compounds include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 18 (IL-18), interferon gamma, interferon gamma inducing factor I (IGIF), transforming growth factor beta (TGF- $\beta$ ), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), Leishmania elongation initiating factor (LEIF), B7-1, B7-2, CD40, CD40 ligand, ICAM-1, and VCAM.

A composition of the present invention includes a cationic lipid complexed with a nucleic acid molecule encoding an antigen in order to elicit or enhance an immune response to the antigen. As used herein, a cationic lipid is a lipid which has a cationic, or positive, charge at physiologic pH. Cationic lipids can have a variety of forms, including liposomes or micelles. Whether a cationic lipid occurs primarily as a liposome or a micelle can be manipulated by methods known in the art; for example, a freezing and thawing of cationic lipids in aqueous solution will encourage formation of liposomes, rather than micelles. A nucleic acid molecule complexed with a cationic lipid may also be referred to as a nucleic acid molecule-cationic lipid complex, a

lipoplex or a complex of the present invention. A complex of the present invention that elicits an immune response is a complex of a nucleic acid molecule which encodes an antigen with a cationic lipid. As used herein, the term complexed with, which is equivalent to complexed to, refers to any method by which a nucleic acid molecule

5 interacts (e.g. binds, comes into contact with a cationic lipid.) Such an interaction can include, but is not limited to encapsulation of a nucleic acid molecule into a cationic liposome, association of a nucleic acid molecule and cationic lipid characterized by non-covalent, ionic charge interactions, and other types of associations between nucleic acid molecules and cationic lipids known by those skilled in the art. It is preferred that

10 cationic lipids have a cationic group, such as a quaternary amine group, and one or more lipophilic groups, such as saturated or unsaturated alkyl groups having from about 6 to 30 carbon atoms. Cationic lipid compositions suitable for use in the present invention include lipid compositions comprised of one type of lipid, or lipid compositions comprised of more than one type of lipid. If there is more than one type of lipid present

15 in a lipid composition, it is necessary that the overall net charge of the lipid composition is cationic, i.e. positive; however, as long as the overall net charge of the lipid composition is cationic, individual lipid types may be neutral or even anionic in charge. A composition of the present invention includes a cationic lipid that is suitable in accordance with the present invention. Cationic lipids suitable for use in the present

20 invention include commercially available cationic lipids, for example DOTMA, available under the trademark name of LIPOFECTIN®, available from Life Technologies Inc., (LTI), Gaithersburg, MD and DDAB, available from Boehringer-Mannheim, Indianapolis, IN. In addition, suitable cationic lipids can be synthesized as described in the literature; see, for example, Felgner et al., 1987, PNAS 84 7413-7417

25 regarding the preparation of DOTAP; Douar et al, 1996, Gene Ther 3(9), 789-796 regarding the preparation of Lipid 67; Wheeler et al., 1996, Biochim Biophys Acta 1280(1), 1-11 regarding the preparation of DMRIE; McLean et al., 1997 Am J Physiol 273, H387-404 regarding the preparation of DOTIM; and Hofland et al., 1997, Pharm Res 14(6), 742-749 regarding the preparation of DOSPA. Other suitable cationic lipid

30 compounds are described in the literature. See, for example, Stamatatos et al., 1988, Biochemistry 27, 3917-3925 and Eibl, et al., 1979, Biophysical Chemistry 10, 261-271.

Preferred cationic lipids include the class of lipids known as tetramethyltetraalkyl spermine analogs, described by McCluskey et al., (1998), *Antisense and Nucleic Acid Drug Development*, vol. 8, pp 401-414. Lipids of this type include

tetramethyltetralaurylspermine, tetramethyltetramyristylspermine,

5 tetramethyltetrapalmitoylspermine, and tetramethyltetraoleoylspermine. The following lipids, obtained from LTI are of the tetramethyltetraalkyl spermine class, with the alkyl groups containing fatty acid chains of length longer than oleic acid. These lipids are denoted as LTI lipids 4251-781-1, 4251-106-3, 4518-52, D304-200, 4521-52-3, 4251-106-4, 4251-781-2, 4518-53, 4518-31, 4519-30, 4519-34, and 2518-111.

10 Preferred cationic lipids include LTI lipid 4251-781-1, LTI lipid 4251-106-3, and LTI lipid 4518-52. In one embodiment, tetramethyltetraalkyl spermine lipids are formulated with a neutral lipid, such as dioleylphosphatidyl-ethanolamine (DOPE).

A nucleic acid molecule-cationic lipid complex can be formed by using techniques known to those skilled in the art, examples of which are described in the

15 Examples section. A complex can be formed, for example, by adding a cationic lipid solution to a nucleic acid molecule, preferably an endotoxin-free nucleic acid molecule, at concentrations appropriate for the present invention, and mixing, for example by pipetting. Preferable nucleic acid molecule-to-cationic lipid ratios are from about 10:1 weight nucleic acid molecule: weight cationic lipid, (e.g. microgram ( $\mu\text{g}$ ) nucleic acid molecule to  $\mu\text{g}$  cationic lipid) to about 1:10 weight nucleic acid molecule: weight cationic lipid. More preferable are ratios from about 1:2 weight of nucleic acid molecule: cationic lipid to about 4:1 weight of nucleic acid molecule: cationic lipid. In a preferred embodiment, the nucleic acid molecule-cationic lipid complex is incubated at room temperature for about 30 minutes before administration. A nucleic acid molecule-cationic lipid complex can be dehydrated and rehydrated using techniques known to those skilled in the art; for example, the complex can be frozen in liquid nitrogen and lyophilized at 150 milliTor, then reconstituted in solution for injection.

A dose of a nucleic acid molecule-cationic lipid complex to administer to a cat can be reported as the amount of nucleic acid molecule administered to a cat. A

30 preferred dose of a nucleic acid molecule-cationic lipid complex to administer to a cat includes from at least one nanogram (ng) of nucleic acid to about 10 milligram (mg) of

nucleic acid molecule. More preferred is a dose range that includes from about 1  $\mu$ g nucleic acid molecule to about 1 mg of nucleic acid molecule. Particularly preferred is a dose ranging from about 75  $\mu$ g of a nucleic acid molecule to about 300  $\mu$ g of a nucleic acid molecule.

5 A nucleic acid molecule-cationic lipid complex composition of the present invention can be formulated in an excipient that the animal to be treated can tolerate. As such, the present invention includes administration of a composition comprising a nucleic acid molecule-cationic lipid complex, wherein the composition further comprises an excipient. Examples of such excipients include water, saline, Ringer's  
10 solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, mannitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate  
15 buffer, bicarbonate buffer and Tris buffer. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.

20 In one embodiment of the present invention, the nucleic acid molecule-cationic lipid complex can also include an adjuvant and/or a carrier. One advantage of a nucleic acid molecule-cationic lipid complex is that adjuvants and carriers are not required to produce a composition that administration thereof will elicit an immune response. However, it should be noted that use of adjuvants or carriers is not precluded by the  
25 present invention. Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxins, such as cholera toxin; toxoids, such as cholera toxoid; serum proteins; other viral coat proteins; other bacterial-derived  
30 preparations; block copolymer adjuvants, such as Hunter's Titermax™ adjuvant (Vaxcel™, Inc. Norcross, GA); Ribi adjuvants (available from Ribi ImmunoChem

Research, Inc., Hamilton, MT); and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark). Carriers are typically compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release formulations, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols.

An immune response to an antigen includes a humoral, i.e. antibody, response to that antigen and/or a cell-mediated response to that antigen. Methods to measure an immune response are known to those skilled in the art; examples of such methods are disclosed herein. If one or both types of immune response are present, they may protect the felid from disease caused, for example, by the agent from which the antigen was derived. In accordance with the present invention, the ability of an antigen derived from a disease-causing agent to protect an animal from a disease caused by that disease-causing agent or a cross-reactive agent refers to the ability of a nucleic acid molecule-cationic lipid complex of the present invention to treat, ameliorate and/or prevent disease caused by the disease-causing agent or cross-reactive agent, preferably by eliciting an immune response against the antigen derived from the disease-causing agent. It is to be noted that an animal may be protected by a composition of the present invention even without the detection of a humoral or cell-mediated response to the antigen. Protection can be measured by methods known to those skilled in the art, such as by challenging an animal with the agent against which the animal has mounted a putative immune response. In certain cases, the antibody titer of an animal can be used to demonstrate protection. For example, it is known that animals that elicit an antibody response against a rabies glycoprotein G antigen are protected if their sera exhibits a rapid focus fluorescent inhibition test (RFFIT) titer of rabies virus neutralizing antibodies of greater than 1:5. As used herein, an animal that elicits an immune response to an antigen is an animal that has been immunized with that antigen.

The biological mechanism for eliciting and/or enhancing an immune response by the use of a nucleic acid molecule-cationic lipid complex composition of the present invention has not been elucidated, but, without being bound by theory, the inventors believe that the mechanism is likely related to the ability of these compositions to protect DNA from nuclease attack, to facilitate the transfection of both muscle cells and

professional antigen presenting cells (APC) *in vivo*, to increase levels of expression in transfected cells, and/or to distribute DNA to lymphoid organs.

A felid, as used herein, is a member of the family Felidae. Examples of felids include domestic cats, wild cats, and zoo cats. Examples of cats, include, but are not  
5 limited to, domestic cats, lions, tigers, leopards, panthers, cougars, bobcats, lynx, jaguars, cheetahs, and servals. A preferred cat to immunize is a domestic cat. The term cat(s) and felid(s) are used interchangeably herein.

As used herein, parenteral administration means administration not through the alimentary canal (e.g. oral administration), but rather by injection through some other  
10 route, including but not limited to routes such as subcutaneous, intramuscular (I.M.), intravenous (I.V.), intraperitoneal (I.P.), intradermal (I.D.), intraorbital, intracapsular, intraspinal, and intrasternal. Parenteral administration includes, but is not limited to, administration by any route that includes use of a needle to insert material into the body. Parenteral administration also includes uses of devices other than a syringe and needle to  
15 insert material through the skin and or mucosal surfaces into the body, including but not limited to the BIOJECTOR®, POWDERJECT, and MEDJECT® needleless injection systems. A preferred route of administration includes intramuscular administration using a needle and syringe.

Acceptable protocols to administer therapeutic compositions in an  
20 effective manner include individual dose size, number of doses, and frequency of dose administration. Typically, the first administration of a composition intended to elicit an immune response is called the primary (or prime) administration, also known as the pre-boost. Additional administrations intended to "boost" or increase an immune response to an antigen are termed booster administrations. Determination of a protocol to elicit an  
25 immune response in a cat using a nucleic acid molecule-cationic lipid complex of the present invention can be accomplished by those skilled in the art. In one embodiment of the present invention, a nucleic acid molecule encoding a desired antigen complexed with cationic lipid need only be administered once by a route appropriate to the present invention (e.g. parenteral) to stimulate an immune response against the antigen. In a  
30 preferred embodiment, such an administration protects the felid from the agent from

which the antigen was derived or from an agent against which the immune response is cross-protective.

In one embodiment, administration of a complex of the present invention to a felid in order to elicit an immune response actually enhances the immune response generated by the felid as compared to the immune response generated upon administration of a naked DNA vaccine to a felid, wherein the naked DNA vaccine consists essentially of a naked DNA molecule; i.e., a DNA molecule that is not complexed with lipids. Finding that a complex of the present invention enhances an immune response is surprising both in view of the conflicting studies known to those skilled in the art as described herein as well as in view of the studies described in more detail in the Examples, in which administration of naked DNA vaccines to cats elicited immune responses in only some cats within each group, or population, tested, whereas administration of a complex of the present invention could result in up to 100% seroconversion of all cats in a population tested. As used herein, enhancement of the immune response can include increasing the amount, or titer, of antibody elicited by a complex of the present invention that encodes an antigen to the desired antigen and/or agent from which the antigen was derived as compared to the titer of antibody generated by a naked DNA vaccine that encodes the same antigen. In one embodiment, such an enhancement can be induction of no antibody titer with a naked DNA vaccine to induction of a protective antibody titer with a complex of the present invention. Enhancement of an immune response can also refer to augmentation of the cell-mediated response to the antigen and/or agent encoded by a complex of the present invention as compared to the response generated by a naked DNA vaccine encoding the same antigen. Enhancement of immune response can also include conferring or augmenting protection from disease by a complex of the present invention compared to the protection, if any, conferred by a naked DNA vaccine encoding the same antigen. In one embodiment, enhancement of the immune response includes increasing the likelihood of a cat seroconverting in response to antigen encoded by a complex of the present invention in comparison to the likelihood of the cat responding to the same antigen encoded by a naked DNA vaccine. In other words, in a group of cats being vaccinated with a complex of the present invention, a greater number of cats will

seroconvert in response to antigen encoded by the complex rather than to the same antigen encoded by a naked DNA vaccine. Preferably, the likelihood that a cat will seroconvert when administered a single dose of a complex of the present invention that encodes an antigen is at least about 50%, preferably at least about 75%, more preferably at least about 90% and even more preferably at least about 100%. In the case where a primary and booster administration of the complex is administered, the likelihood that a cat will seroconvert is preferably at least about 75%, more preferably at least about 90%, and even more preferably at least about 100%.

The present invention includes a method to administer a nucleic acid molecule to a felid. The method includes the step of parenterally administering a composition comprising said nucleic acid molecule complexed with a cationic lipid. Such a nucleic acid molecule can encode either a protein or a RNA molecule. In one embodiment, the nucleic acid molecule encodes a protein or RNA molecule that, when expressed at an appropriate level, has a protective effect upon the cat. As used herein, a protein refers to a full-length protein or any portion thereof that is at least about 5 amino acids in length and has a useful function, including, but not limited to, ability to elicit an immune response, elicit an immunomodulatory effect (e.g., an immunomodulator that stimulates or reduces the immune response), effect gene therapy, effect enzyme activity, or otherwise effect cell division, differentiation, development and cell death. As used herein, a RNA molecule refers to any RNA species that can be encoded by a nucleic acid molecule, including, but not limited to antisense RNA, a molecule capable of triple helix formation, a ribozyme, or other nucleic acid-based drug compound. As such, any protein or RNA molecule that can be expressed at an appropriate level in a cat, which protects a cat from disease, would be included in this invention. Diseases from which to protect a felid include, but are not limited to, infectious diseases, genetic diseases, oncological diseases, and other metabolic diseases, including diseases that lead to abnormal cell growth, degenerative processes, and immunological defects. Compositions of the present invention can protect animals from a variety of diseases including, but not limited to, allergies, arthritic diseases, autoimmune diseases, cancers, cardiovascular diseases, graft rejection, hematopoietic disorders, immunodeficiency diseases, immunoproliferative diseases, immunosuppressive disorders, infectious

diseases, inflammatory diseases, jaundice, septic shock, and other immunological defects, as well as other genetic or metabolic defects. Methods to produce and use a composition comprising any nucleic acid molecule of the present invention complexed with any cationic lipid of the present invention are as described herein.

5       The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.

### EXAMPLES

#### Example 1

10       This Example demonstrates the production of a nucleic acid molecule of the present invention.

15       A nucleic acid molecule encoding human growth hormone (hGH) was constructed using plasmid pHGH107 (available from American Type Culture Collection, Manassas, VA), which encodes hGH amino-acids 1-191, as a polymerase chain reaction (PCR) template. The hGH open reading frame was amplified by PCR using Pfu DNA polymerase (available from Stratagene, La Jolla, CA) and the following forward and reverse primers: 5' TTCCCAACTATACTACTATCTCGTCTA 3' (SEQ ID NO:1) and 5' CTAGAAGCCACAGCTGCCCTCCACAGAG 3' (SEQ ID NO:2). The PCR product containing the sequence encoding the mature hGH product was ligated into the *NaeI* site of a plasmid containing the human cytomegalovirus immediate early promoter, a translation control sequence, a sequence encoding the signal peptide coding sequence from human tissue plasminogen activator, and a bovine growth hormone poly A sequence. The expression of hGH from this plasmid was confirmed following transfection of cells *in vitro* and was detected using a chemiluminescence assay kit (available from Nichols Institute Diagnostics, San Juan Capistrano, CA).

25       A nucleic acid molecule encoding the rabies virus glycoprotein G was described previously and contains the CMV intron A promoter, the rabies glycoprotein G coding sequence, and the bovine growth hormone polyadenylation sequence. See Osorio, et al. (1999) Vaccine, in press.

#### Example 2

30       This Example describes the production of a nucleic acid molecule-cationic lipid complex of the present invention.

Endotoxin-free nucleic acid molecules encoding hGH or rabies glycoprotein G were prepared using a commercial kit (Qiagen, Inc., Valencia, CA) and the resulting nucleic acid molecules were dissolved in endotoxin-free 10 mM Tris-HCl, pH 7.5, 1 mM EDTA at 2 mg per milliliter (ml) to form a hGH nucleic acid molecule solution and a rabies gG nucleic acid molecule solution, respectively. Cationic lipids 4251-106-3 (also known as 106-3), 4251-781-1 (also known as 781-1), and 4518-52 were obtained from Life Technologies, Inc. (LTI), Gaithersburg, MD. A nucleic acid molecule-cationic lipid complex was formed by adding 250  $\mu$ l of the respective cationic lipid solution to 250  $\mu$ l of the respective nucleic acid molecule solution, followed by immediate mixing by pipetting. The concentrations of the cationic lipid solutions and of the nucleic acid molecule solutions used were adjusted to give the desired amounts and ratios of nucleic acid molecules to cationic lipids described elsewhere in the Examples. The mixture was incubated at room temperature for 30 minutes before administration. For dehydration and rehydration of a nucleic acid molecule-cationic lipid complex, the complex was frozen in liquid nitrogen and lyophilized at 150 mTorr, then reconstituted in the original volume of sterile water for injection.

### Example 3

This Example describes a method for administering a nucleic acid molecule-cationic lipid complex of the present invention to a felid.

Primary and booster administrations of nucleic acid molecule-cationic lipid complexes prepared as described in Example 2 were injected intramuscularly into the semitendinosus or semimembranosus muscle of domestic cats. Each dose was divided into two equal portions and administered bilaterally into each leg. Sera samples were collected every 10 days for antibody determination.

### Example 4

This Example describes methods to measure immune responses generated in response to the administration of nucleic acid molecule-cationic lipid complexes of the present invention.

Antibody responses specific for hGH were determined by ELISA. Briefly, ELISA plate wells were coated with 0.4 micrograms ( $\mu$ g) hGH protein per well (hGH protein available from Genzyme Diagnostics, San Carlos, CA) and incubated overnight

at 4°C. Unbound antigen was aspirated and the plate was blocked with 2% skimmed milk for 1 hour at 37°C. ELISA plates were washed 3 times with TBS-Tween (150 milliMolar (mM) NaCl, 50 mM Tris-HCl (pH 8.0), 0.1% TWEEN-20) and serially diluted sera samples from vaccinated cats were added and incubated at 37°C for 1 hour.

- 5 Plates were washed 3 times with TBS-Tween. A biotin conjugated monoclonal anti-cat IgG (1:30,000) (available from Sigma-Aldrich, St. Louis, MO), was added and incubated for 1 hour at 37°C, followed by the addition of EXTRAVIDIN®-horseradish peroxidase diluted 1:1000, available from Sigma-Aldrich, St. Louis, MO. After a final incubation at 37°C, for 1 hour, the plates were washed and an o-phenylenediamine dihydrochloride  
10 substrate solution, available from Sigma-Aldrich, was added and the plates incubated at room temperature for 30 minutes for color development. The plates were read at 450 nm.

- Rabies virus-specific neutralizing antibody response were determined using the Rapid Fluorescent Focus Inhibition test (RFFIT) at the Department of Veterinary  
15 Diagnostics, Kansas State University.

- T cell proliferation assays were carried out in the following manner. Heparinized blood samples were collected from cats a week after administration of a booster injection as described in Example 5. The lymphocytes were isolated from the blood samples using a percoll gradient (Sigma Chemicals, St Louis, MO). The isolated  
20 lymphocytes were resuspended in RPMI 1640 (Sigma Chemical) containing 5% normal cat serum, 2 mM L-glutamine (Life Technologies, Bethesda, MD), 1 mM sodium pyruvate (Life Technologies), 50 µM 2-mercaptoethanol (Life Technologies), 5 µg/mL gentamycin (Sigma Chemical), 0.1 mM MEM non-essential amino acids (Life Technologies), and 1% essential amino acids (Life Technologies) plated at a density of  
25  $2 \times 10^5$  cells/well and treated with various concentrations of recombinant human growth hormone (hGH) (Genzyme Diagnostics, Boston, MA) for a total of 3 or 5 days. Each group of cell samples contained a negative control (media alone) and a positive control (Concanavalin A, Sigma Chemicals). Cells were pulsed at time of measurement with 0.5 µCurie of tritiated thymidine (ICN Pharmaceuticals) per well. T cells that were  
30 specific for hGH proliferated in response to added hGH and incorporated the tritiated thymidine into their DNA. The amount of incorporated tritium was counted 16 to 18

hours post-pulse in a scintillation counter. Data was reported as the stimulation index, which was derived by dividing the counts per minute obtained from the samples divided by the counts per minute obtained from the negative control.

#### Example 5

5        This Example compares the immune response elicited using a nucleic acid molecule encoding hGH complexed with either LTI lipid 781-1 or LTI lipid 106-3 to the immune response elicited using a naked DNA vaccine encoding hGH in cats.

10        The hGH nucleic acid molecule was complexed with LTI lipid 781-1 at a lipid-to-DNA ratio ( $\mu\text{g}:\mu\text{g}$ ) of 0.5:1.0, and formulated with LTI lipid 106-3 at a lipid-to-DNA ratio of 1:1, as described in Example 2. The naked DNA vaccine consisted of the hGH nucleic acid molecule prepared as described in Example 2 dissolved in saline.

A total of 12 cats were divided into three vaccine groups as follows:

15        Group 1 (naked DNA): Two injections, spaced 8 weeks apart, of 300  $\mu\text{g}$  of naked hGH nucleic acid molecule in 500  $\mu\text{l}$  saline.

20        Group 2 (LTI lipid 781-1): Two injections, spaced 8 weeks apart, of 300  $\mu\text{g}$  hGH nucleic acid molecule complexed with 150  $\mu\text{g}$  cationic lipid.

25        Group 3 (LTI lipid 106-3): Two injections, spaced 8 weeks apart, of 300  $\mu\text{g}$  hGH nucleic acid molecule complexed with 300  $\mu\text{g}$  cationic lipid.

30        At day 54 post injection, the cats were boosted with another injection of the appropriate cationic lipid-DNA mixture. At day 111, cats were boosted again, and at day 119, T-cell proliferation assays were performed as described. A T-cell stimulation index of 2 is taken as the cutoff and values below 2 are considered non-responsive.

35        Sera samples were collected from cats following the primary and booster administrations of complex as described in Example 3 and were assayed for hGH specific antibody responses by ELISA. Endpoint ELISA titers are shown in Table 1. The lowest sera titers measured were 1:40. Therefore, negative titers are expressed as <1:40.

Table 1. hGH antibody titers of sera samples collected from cats administered a naked DNA vaccine or a complex of the present invention encoding hGH

cat #	Formulation	Titer at day 54 (post prime)	Titer at day 64 (post boost)	T-cell stimulation index
1	Naked DNA	<1:40	<1:40	9.1
2	Naked DNA	<1:40	<1:40	2.4
3	Naked DNA	<1:40	1:1125	12.7
4	Naked DNA	<1:40	<1:40	11.3
		geometric mean=40	geometric mean=92	
5	DNA + lipid 781-1	<1:40	<1:40	1.6
6	DNA + lipid 781-1	1:160	1:10,240	20.2
7	DNA + lipid 781-1	1:2312	1:7762	3.7
8	DNA + lipid 781-1	1:233	1:21,183	8.9
		geometric mean=242	geometric mean=2865	
9	DNA + lipid 106-3	1:1076	1:19,000	24.3
10	DNA + lipid 106-3	1:316	1:19,135	65.5
11	DNA + lipid 106-3	<1:40	<1:40	18.2
12	DNA + lipid 106-3	1:125	1:8693	2.6
		geometric mean=203	geometric mean=3353	

The results in Table 1 indicate that there was no seroconversion in any of the four cats administered a single inoculation of 300  $\mu$ g of the naked hGH nucleic acid molecule. Moreover, following the booster administration, only one of the four cats in the naked DNA vaccine group developed an hGH-specific antibody response. In contrast to the naked DNA vaccine group, 75% of the cats (i.e., 3 of 4 cats) in each of the two lipid groups developed detectable titers following the primary administration of complex, and these responses went up markedly following the booster administration of complex.

T-cell proliferation, measured by the T cell stimulation index, indicates that all treatments, including treatment with DNA alone, appeared to activate cell-mediated immunity. Treatment with a complex of DNA and lipid 106-3 appears to work better for

stimulating T cell proliferation in cats than did naked DNA alone or DNA complexed with lipid 781-1.

#### Example 6

This Example compares immune responses elicited using a nucleic acid molecule encoding rabies glycoprotein G complexed with several cationic lipids of the present invention to the immune response elicited using a naked DNA vaccine encoding rabies glycoprotein G in cats.

This example compared the abilities of the following compositions to elicit an immune response against rabies glycoprotein G (rabies G) in cats: a naked DNA vaccine consisting of the rabies G nucleic acid molecule; and complexes between the rabies G nucleic acid molecule and one of the following cationic lipids: LTI lipid 106-3, LTI lipid 781-1, or LTI lipid 4518-52, each at a variety of DNA:lipid ratios. Also tested was a complex that had been dehydrated by lyophilization and rehydrated prior to administration. Each of the compositions was produced as described in Example 2. All cats received two intramuscular injections as described in Example 3, spaced four weeks apart. The following groups of 4 cats each were tested:

Group 1: Naked DNA, 300  $\mu$ g rabies G vector

Group 2: 300  $\mu$ g lipid 781-1 + 300  $\mu$ g rabies G vector

Group 3: 150  $\mu$ g lipid 781-1 + 300  $\mu$ g rabies G vector

Group 4: 75  $\mu$ g lipid 781-1 + 300  $\mu$ g rabies G vector

Group 5: 600  $\mu$ g lipid 106-3 + 300  $\mu$ g rabies G vector

Group 6: 300  $\mu$ g lipid 106-3 + 300  $\mu$ g rabies G vector

Group 7: 150  $\mu$ g lipid 106-3 + 300  $\mu$ g rabies G vector

Group 8: 300  $\mu$ g lipid 4518-52 + 300  $\mu$ g rabies G vector

Group 9: 300  $\mu$ g lipid 106-3 + 300  $\mu$ g rabies G vector (lyophilized and rehydrated)

Group 10: 75  $\mu$ g lipid 106-3 + 75  $\mu$ g rabies G vector.

Group 1 served as a control group to demonstrate immunogenicity of the naked DNA vaccine. Groups 2-4 were designed to determine if differences in the lipid-to-DNA ratio were important for lipid 781-1. Similarly, groups 5-7 were designed to determine if differences in the lipid-to-DNA ratio were important for lipid 106-3.

Group 8 was included to examine the efficacy of LTI lipid 4518-52. Group 9 was included to determine if lyophilization and rehydration of lipid:DNA complexes would improve cationic lipid vaccine efficacy in cats as previously demonstrated in mice by Gregoriadis, *ibid*. Finally, group 10 was included to determine is less than 300  $\mu$ g of DNA could be used without affecting the ability of lipid 106-3 to enhance the ability of cats to elicit an immune response.

Rabies virus-specific neutralizing antibody activity was measured in the sera of all cats before and after the booster administration by RFFIT. Sera dilutions tested ranged from 1:5 to 1:174,693. Negative responses are listed as a titer of <1:5 while responses that are stronger than the final dilution tested are indicated by the ">" sign. Injections were made intramuscularly. It is known to those skilled in the art that an anti-rabies G antibody titer of 1:5 or greater, as measured by RFFIT, is protective. Results from these studies are shown in Table 2.

Table 2. Rabies G antibody titers of sera samples collected from cats administered a naked DNA vaccine or a complex of the present invention encoding rabies G.

Group 1

cat #	Formulation	Titer Pre-boost	Titer Post-boost
QHR5	Naked DNA (300 $\mu$ g rabies G)	<1:5	1:25
BWM3	Naked DNA (300 $\mu$ g rabies G)	<1:5	<1:5
3042	Naked DNA (300 $\mu$ g rabies G)	<1:5	1:1400
ABO2	Naked DNA (300 $\mu$ g rabies G)	<1:5	<1:5

Group 2

cat #	Formulation	Titer Pre-boost	Titer Post-boost
QHH1	300 $\mu$ g DNA + 300 $\mu$ g lipid 781-1	1:7000	1:167,449
3102	300 $\mu$ g DNA + 300 $\mu$ g lipid 781-1	1:1800	1:167,449
S72	300 $\mu$ g DNA + 300 $\mu$ g lipid 781-1	<1:5	1:50
QJB1	300 $\mu$ g DNA + 300 $\mu$ g lipid 781-1	<1:5	1:230

## Group 3

cat #	Formulation	Titer Pre-boost	Titer Post-boost
QHN4	300 $\mu$ g DNA + 150 $\mu$ g lipid 781-1	<1:5	1:1400
QIN5	300 $\mu$ g DNA + 150 $\mu$ g lipid 781-1	1:2200	1:42,724
QGN5	300 $\mu$ g DNA + 150 $\mu$ g lipid 781-1	1:625	1:113,264
QHG1	300 $\mu$ g DNA + 150 $\mu$ g lipid 781-1	<1:5	1:7000

## Group 4

cat #	Formulation	Titer Pre-boost	Titer Post-boost
QHR1	300 $\mu$ g DNA + 75 $\mu$ g lipid 781-1	<1:5	1:50
QIN2	300 $\mu$ g DNA + 75 $\mu$ g lipid 781-1	1:280	1:5100
QGR5	300 $\mu$ g DNA + 75 $\mu$ g lipid 781-1	1:2400	1:6000
ACN1	300 $\mu$ g DNA + 75 $\mu$ g lipid 781-1	<1:5	1:125

## Group 5

cat #	Formulation	Titer Pre-boost	Titer Post-boost
3603	300 $\mu$ g DNA + 600 $\mu$ g lipid 106-3	1:7000	1:174,693
BNJ2	300 $\mu$ g DNA + 600 $\mu$ g lipid 106-3	<1:5	1:1800
ZAH1	300 $\mu$ g DNA + 600 $\mu$ g lipid 106-3	1:5100	1:159,751
S203	300 $\mu$ g DNA + 600 $\mu$ g lipid 106-3	1:6300	1:67,491

## Group 6

cat #	Formulation	Titer Pre-boost	Titer Post-boost
3525	300 $\mu$ g DNA + 300 $\mu$ g lipid 106-3	1:280	1:45,668
BNJ1	300 $\mu$ g DNA + 300 $\mu$ g lipid 106-3	1:125	1:6800
BMX2	300 $\mu$ g DNA + 300 $\mu$ g lipid 106-3	<1:5	1:6800
S197	300 $\mu$ g DNA + 300 $\mu$ g lipid 106-3	>1:167,449	1:6800

## Group 7

cat #	Formulation	Titer Pre-boost	Titer Post-boost
3553	300 $\mu$ g DNA + 150 $\mu$ g lipid 106-3	1:1100	1:53,888
BN13	300 $\mu$ g DNA + 150 $\mu$ g lipid 106-3	<1:5	1:3125
E490	300 $\mu$ g DNA + 150 $\mu$ g lipid 106-3	1:25	1:6800
S192	300 $\mu$ g DNA + 150 $\mu$ g lipid 106-3	1:40	1:6000

## Group 8

cat #	Formulation	Titer Pre-boost	Titer Post-boost
3541	300 $\mu$ g DNA+300 $\mu$ g lipid 4518-52	1:45	1:7000
BNH4	300 $\mu$ g DNA+300 $\mu$ g lipid 4518-52	1:1200	1:142,858
BLR1	300 $\mu$ g DNA+300 $\mu$ g lipid 4518-52	1:280	1:7000
S189	300 $\mu$ g DNA+300 $\mu$ g lipid 4518-52	>1:7000	1:159,751

## Group 9

cat #	Formulation	Titer Pre-boost	Titer Post-boost
	DNA + lipid 106-3, dehyd & rehyd <sup>1</sup>	1:2700	1:142,858
BNF4	DNA + lipid 106-3, dehyd & rehyd <sup>1</sup>	1:170	>1:167,449
E457	DNA + lipid 106-3, dehyd & rehyd <sup>1</sup>	1:1400	1:8,125
S186	DNA + lipid 106-3, dehyd & rehyd <sup>1</sup>	1:45	1:3,125

<sup>1</sup>300  $\mu$ g rabies G DNA + 300  $\mu$ g lipid 106-3/dehydrated and rehydrated by the method of Gregoriadis, et al., *ibid*.

## 20 Group 10

cat #	Formulation	Titer Pre-boost	Titer Post-boost
BMC1	DNA, 75 $\mu$ g + lipid 106-3, 75 $\mu$ g	1:1800	1:6000
E451	DNA, 75 $\mu$ g + lipid 106-3, 75 $\mu$ g	1:3125	1:38,206
QNV1	DNA, 75 $\mu$ g + lipid 106-3, 75 $\mu$ g	1:360	1:34,600
ZAF1	DNA, 75 $\mu$ g + lipid 106-3, 75 $\mu$ g	1:440	1:5,400

Geometric Mean Titers for each group, pre-boost and post boost, for each group

Group	Formulation	mean titer, pre-	mean titer, post-
1	Naked DNA (300 $\mu$ g)	<5	30.6
2	DNA, 300 $\mu$ g + lipid 781-1, 300 $\mu$ g (1:1)	133	4238
3	DNA, 300 $\mu$ g + lipid 781-1, 150 $\mu$ g (1:0.5)	77	14,756
4	DNA, 300 $\mu$ g + lipid 781-1, 75 $\mu$ g (1:0.25)	64	661
5	DNA, 300 $\mu$ g + lipid 106-3, 600 $\mu$ g (1:2)	1029	42,910
6	DNA, 300 $\mu$ g + lipid 106-3, 300 $\mu$ g (1:1)	413	10,409
7	DNA, 300 $\mu$ g + lipid, 106-3, 150 $\mu$ g (1:0.5)	48	9104
8	DNA, 300 $\mu$ g + lipid 4518-52, 300 $\mu$ g (1:1)	570	32,518
9	DNA, 300 $\mu$ g + lipid, 106-3, 300 $\mu$ g dehyd& rehyd <sup>1</sup>	412	49,159
10	DNA, 75 $\mu$ g + lipid 106-3, 75 $\mu$ g (1:1)	972	14,385

The data presented in Table 2 support the following conclusions: (1) in the cats receiving the naked DNA vaccine, no seroconversion was observed following the primary administration of vaccine immunization. In contrast, all of the cats receiving a nucleic acid molecule - cationic lipid complex of the present invention exhibited seroconversion after the booster administration, and at least 50% of the cats seroconverted per group after the initial administration of the complex. The best seroconversion was seen in groups 8, 9, and 10 in which 100% seroconversion was observed following the primary administration of complex. These results (0% seroconversion in group 1 and 100% seroconversion in groups 8-10 following the primary administration) were statistically significant by Fisher's exact test ( $P < 0.05$ ).

(2) Following the booster administration, all nine groups that were administered a complex of the present invention exhibited stronger responses than the naked DNA vaccine control group. Despite the small number of cats in each group, statistically significant enhancement by Student's t test was observed in groups 5 and 9 as compared to group 1, i.e. naked DNA vaccine. (3) Varying the ratio of lipid-to-DNA did not have significant impact on the degree of enhancement (groups 2-4 and 5-7). (4) Dehydration and rehydration of the lipid:DNA complexes (lipid 106-3) prior to inoculation resulted

in 100% seroconversion following the primary administration and very strong responses in all cats following the boost (group 9). (5) Reducing the DNA dosage to 75  $\mu$ g from 300  $\mu$ g did not result in any loss of the enhancement potential since 100% seroconversion was observed after the primary administration of the complex and very strong responses were observed in all cats post-boost (group 10).

Example 7. Measuring luciferase expression in cat muscle.

Muscle and lymph node tissues were dissected and removed from the thigh of a sacrificed cat, see Example 3. The tissues were quick frozen on dry ice, and ground to a powder in liquid nitrogen. Ground frozen tissue was resuspended in 1X cell culture lysate reagent (25 mM Tris-Phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100). After lysis, the cell debris was removed by centrifugation and supernatant was used in the following assay. An aliquot of the supernatant was mixed with Luciferase Assay Reagent, (Promega, Madison, WI). The mixture was placed in a Turner Designs Luminometer TD-20/20, (Promega), and the light emitted was measured for 15 seconds. The standard used to calibrate the assay was the recombinant firefly luciferase QUANTILUM™, (Promega).

Example 8. Comparison of expression of a DNA plasmid, formulated with and without LTI lipid 106-3, in the cat muscle.

In this example, evidence for increased antigen expression in the muscle upon formulation with lipid 106-3 was observed in an experiment in which 300  $\mu$ g of a plasmid vector encoding luciferase was injected into each semimembranosus muscle (inner thigh) of a cat, one muscle receiving DNA complexed with lipid, and one muscle receiving naked DNA. In the case of DNA formulated with lipid 106-3, 300  $\mu$ g of DNA was formulated with 300  $\mu$ g of lipid 106-3. Specifically, the right thigh of the cat was injected with DNA alone; the left thigh was injected with DNA formulated with lipid 106-3. After 48 hours, the cat was sacrificed, the muscles were dissected and luciferase activity was measured as described in Example 7. Table 3 shows the luciferase assay standard curve used for this experiment, and Table 4 shows luminometer measurements for each dissected tissue in the cat.

Table 3. Luciferase assay standard curve

Sample	Luminometer readings
Blank	0.069
Positive control	332
2.5 $\mu$ g standard	387.9
250 nanogram(ng) standard	54.07
25 ng standard	9.817
2.5 ng standard	1.909
250 picogram (pg) standard	0.431
25 pg standard	0.189

Table 4. Luminometer readings for each dissected muscle

muscle tested	Amount of tissue used in luciferase assay	Luminometer reading
Right superficial muscle (M. gracilis)	140 milligram (mg)	0.044
Right deep muscle (M. semimembranosus)	140 mg	0.065
Right Inguinal lymph node	100 mg	0.040
Right Popliteal lymph node	73 mg	0.052
Left superficial muscle	140 mg	0.058
Left Deep muscle	140 mg	13.82
Left Inguinal lymph node	could not locate	Not determined
Left Popliteal lymph node	80 mg	0.078

While no significant luciferase activity was observed in the leg injected with naked DNA, approximately 2  $\mu$ g total of luciferase was produced in the entire deep muscle of the leg injected with the lipid/DNA formulation (assay sensitivity=2 pg), providing evidence for enhanced gene delivery and antigen production via use of cationic lipid formulations of the present invention.

Example 9. Effect of cationic lipid formulated DNA vaccines in mice.

This example demonstrates that formulation of DNA vaccines with cationic lipids does not enhance nucleic acid efficacy in mice, in contrast to the enhancement of nucleic acid efficacy seen in cats treated with cationic lipid/DNA formulations.

5 Three different nucleic acid molecules, encoding rabies glycoprotein G, were prepared as described in Example 2. The first, pMV 5044, contains the CMV intron A promoter, the rabies glycoprotein G coding sequence, and the rabbit beta globin polyadenylation sequence. The second, pMV 5045, contains the CMV intron A promoter, the rabies glycoprotein G coding sequence, and the bovine growth hormone  
10 polyadenylation sequence. The third, pMV 5046, contains the CMV promoter, the rabies glycoprotein G coding sequence, and the bovine growth hormone polyadenylation sequence.

The three nucleic acid molecules encoding rabies glycoprotein G (rabies G) were complexed with LTI lipid 106-3 at a lipid to DNA ratio ( $\mu\text{g}:\mu\text{g}$ ) of 1:1 as described in  
15 Example 2. The corresponding "naked" DNA vaccines were prepared by dissolving the plasmids in saline.

A total of 30 mice were divided into six vaccine groups as follows:

Group 1 (pMV 5044, 50  $\mu\text{g}$  + lipid): One injection, intramuscular. Antibody titers determined at four weeks post injection.

20 Group 2 (pMV 5044, 100  $\mu\text{g}$  alone): One injection, intramuscular. Antibody titers determined at four weeks post injection.

Group 3 (pMV 5045, 50  $\mu\text{g}$  + lipid): One injection, intramuscular. Antibody titers determined at four weeks post injection.

25 Group 4 (pMV 5045, 100  $\mu\text{g}$  alone): One injection, intramuscular. Antibody titers determined at four weeks post injection.

Group 5 (pMV 5046, 50  $\mu\text{g}$  + lipid): One injection, intramuscular. Antibody titers determined at four weeks post injection.

Group 6 (pMV 5046, 100  $\mu\text{g}$  alone): One injection, intramuscular. Antibody titers determined at four weeks post injection.

Table 5. Anti-rabies G antibody titers of sera samples collected from mice administered a naked DNA vaccine or a complex of the present invention encoding rabies G.

## Group 1

5

mouse #	Formulation	Titer
1	pMV5044, 50 $\mu$ g + Lipid 106-3	1:40
2	pMV5044, 50 $\mu$ g + Lipid 106-3	1:40
3	pMV5044, 50 $\mu$ g + Lipid 106-3	1:51
4	pMV5044, 50 $\mu$ g + Lipid 106-3	1:115
5	pMV5044, 50 $\mu$ g + Lipid 106-3	1:135

10

## Group 2

15

mouse #	Formulation	Titer
1	pMV5044, 100 $\mu$ g alone	1:43
2	pMV5044, 100 $\mu$ g alone	1:53
3	pMV5044, 100 $\mu$ g alone	1:242
4	pMV5044, 100 $\mu$ g alone	1:1060
5	pMV5044, 100 $\mu$ g alone	1:3795

## Group 3

20

mouse #	Formulation	Titer
1	pMV5045, 50 $\mu$ g + Lipid 106-3	1:40
2	pMV5045, 50 $\mu$ g + Lipid 106-3	1:65
3	pMV5045, 50 $\mu$ g + Lipid 106-3	1:68
4	pMV5045, 50 $\mu$ g + Lipid 106-3	1:73
5	pMV5045, 50 $\mu$ g + Lipid 106-3	1:137

## Group 4

mouse #	Formulation	Titer
1	pMV5045, 100 µg alone	1:1
2	pMV5045, 100 µg alone	1:46
3	pMV5045, 100 µg alone	1:100
4	pMV5045, 100 µg alone	1:547
5	pMV5045, 100 µg alone	1:640

## Group 5

mouse #	Formulation	Titer
1	pMV5046, 50 µg + Lipid 106-3	1:1
2	pMV5046, 50 µg + Lipid 106-3	1:1
3	pMV5046, 50 µg + Lipid 106-3	1:1
4	pMV5046, 50 µg + Lipid 106-3	1:34
5	pMV5046, 50 µg + Lipid 106-3	1:54

## Group 6

mouse #	Formulation	Titer
1	pMV5046, 100 µg alone	1:1
2	pMV5046, 100 µg alone	1:1
3	pMV5046, 100 µg alone	1:1
4	pMV5046, 100 µg alone	1:1
5	pMV5046, 100 µg alone	1:59

Rabies-virus specific neutralizing antibody activity was measured by RFFIT in the sera of all mice four weeks after injection with three different nucleic acid molecules containing Rabies glycoprotein G.

The data presented in Table 5 indicate that cationic lipid formulation of a DNA vaccine does not enhance vaccine efficacy, as measured by humoral (antibody) response, in mice. These data are in contrast to results obtained in cats, where vaccine efficacy is enhanced by formulation with cationic lipids. For the nucleic acid construct pMV5044,

formulation with lipid actually appears to slightly reduce DNA vaccine efficacy for mice, with the geometric means (of the five mice per group) declining from 294 with DNA alone to 66 with DNA/lipid complex. Results from the other two constructs in mice also showed no increase in efficacy; the geometric means were as follows: for 5 pMV5045, 69.4 for DNA alone and 70.7 with DNA/lipid complex; and for pMV5046, 2.3 for DNA alone and 4.5 for DNA/lipid complex.

Example 10. Administration of a DNA plasmid, formulated with and without LTI lipid 106-3, to cats.

This example demonstrates the local immune response at the site of injection of 10 DNA plasmids formulated with or without LTI lipid 106-3. Each of four cats was administered each of the following formulations to each of the following sites on the ventral side: (a) saline (i.e., vehicle alone) to the right arm; (b) 300 µg of lipid 106-3 (lipid alone) to the left arm; (c) 300 µg of a naked plasmid vector encoding rabies glycoprotein G (naked rabies G vector) to the upper right foot; (d) 300 µg of a naked 15 plasmid vector encoding luciferase (naked luciferase vector) to the lower right foot; (e) 300 µg of rabies G vector formulated with 300 µg of lipid 106-3 to the upper left foot; and (f) 300 µg of luciferase vector formulated with 300 µg of lipid 106-3 to the lower left foot.

Six days after administration of the various formulations, the cats were 20 euthanized and muscle and popliteal lymph node muscles were collected. Although the injection sites were marked, it was difficult to obtain muscle samples from the injection sites; thus, only four injection sites were identified, namely those for the saline only and naked rabies G vector in one cat and those for lipid only and rabies G vector plus lipid in another cat. Muscle samples were sectioned using a cryostat and the sections were 25 stained using hematoxylin and eosin to analyze the population of cells infiltrating the sites of injection. Muscle samples were also stained with antibodies specific for B-cells (anti-CD79a antibodies) using techniques known to those skilled in the art.

No differences were seen among the various lymph nodes with respect to cell infiltration. In the muscle samples where vehicle alone, lipid alone or naked rabies 30 G vector was injected, the infiltrating population of cells were mostly macrophage-like cells. In contrast, in the muscle sample where the formulation comprising rabies

G vector complexed with lipid was infected, the infiltrating cells were predominantly lymphocyte-like cells. Staining results with anti-CD79a antibodies suggested that the majority of lymphocytes present were T cells.

These results, as well as others provided herein, suggest that administration of  
5 nucleic acid molecules complexed with cationic lipids to cats leads to enhanced  
expression of the protein encoded by the nucleic acid molecule and infiltration of  
lymphocytes to the injection site which apparently does not occur when naked nucleic  
acid molecules are administered in a similar manner. Without being bound by theory, it  
is believed that this infiltration of lymphocytes might explain the enhanced immune  
10 response seen with nucleic acid molecule-cationic lipid complexes of the present  
invention.

While various embodiments of the present invention have been described in  
detail, it is apparent that modifications and adaptations of those embodiments will occur  
to those skilled in the art. It is to be expressly understood, however, that such  
15 modifications and adaptations are within the scope of the present invention, as set forth  
in the following claims.

What is claimed is:

1. A method to elicit an immune response to an antigen in a felid, said method comprising parenterally administering to said felid a composition comprising a nucleic acid molecule complexed with a cationic lipid, wherein said nucleic acid molecule encodes said antigen.
2. A method to deliver a nucleic acid molecule to a felid, said method comprising parenterally administering a composition comprising said nucleic acid molecule complexed with a cationic lipid.
3. A method to protect a felid from rabies infection, said method comprising parenterally administering to said felid a composition comprising a nucleic acid molecule encoding rabies glycoprotein G, wherein said nucleic acid molecule is complexed with a cationic lipid.
4. The method of Claim 2, wherein said nucleic acid molecule encodes a compound selected from the group consisting of an RNA molecule and a protein.
5. The method of Claim 2, wherein said nucleic acid molecule encodes a protein that elicits an immune response in said felid.
6. The method of Claim 5, wherein said protein is selected from the group consisting of an antigen and an immunomodulator.
7. The method of Claim 1 or 5, wherein said immune response comprises an antibody response.
8. The method of Claim 1 or 5, wherein said immune response comprises a cell-mediated response.
9. The method of Claim 1 or 5, wherein said immune response protects said felid from disease.
10. The method of Claim 1 or 6, wherein said antigen is selected from the group consisting of a protozoan parasite antigen, a helminth parasite antigen, an ectoparasite antigen, a fungal antigen, a bacterial antigen, and a viral antigen.
11. The method of Claim 1 or 6, wherein said antigen is selected from the group consisting of a calicivirus antigen, a coronavirus antigen, a herpesvirus antigen, an immunodeficiency virus antigen, an infectious peritonitis virus antigen, a leukemia virus antigen, a parvovirus antigen, a rabies virus antigen, a *Bartonella* antigen, a *Yersinia*

antigen, a *Dirofilaria* antigen, a *Toxoplasma* antigen, a flea antigen, a flea allergen, a midge antigen, a midge allergen, a mite antigen, a mite allergen, and a tumor antigen.

12. The method of Claim 1 or 6, wherein said antigen comprises rabies glycoprotein G antigen.

5 13. The method of Claim 1, 2, or 3, wherein said cationic lipid comprises a tetramethyltetraalkyl spermine analog lipid.

14. The method of Claim 1 or 3, wherein said composition further encodes an immunomodulator.

10 15. The method of Claim 1, 2, or 3, wherein said felid is selected from the group consisting of domestic cats, wild cats, and zoo cats.

16. The method of Claim 1, 2, or 3, wherein the felid is selected from the group consisting of domestic cats, lions, tigers, leopards, panthers, cougars, bobcats, lynx, bobcats, lynx, jaguars, cheetahs, and servals.

17. The method of Claim 1, 2, or 3, wherein the felid is a domestic cat.

15 18. The method of Claim 1, 3, or 5, wherein a single administration of said composition elicits an immune response.

19. The method of Claim 1, 3, or 6, wherein said step of administering enhances an immune response compared to administration of a naked DNA vaccine encoding said antigen of Claim 1 or 6 or said rabies glycoprotein G of Claim 3 to a felid.

20 20. The method of Claim 1, 2, or 3, wherein said step of administering is selected from the group of intramuscular administration, intravenous administration, subcutaneous administration, intradermal administration, and intraperitoneal administration.

25 21. The method of Claim 1, 2, or 3, wherein said step of administering effects about 75% seroconversion in a population of felids administered said nucleic acid molecule.

22. The method of Claim 1, 2, or 3, wherein said step of administering effects about 100% seroconversion in a population of felids administered said nucleic acid molecule.

23. The method of Claim 1, 2, or 3, wherein said nucleic acid molecule:lipid ratio is from about 1:10 to about 10:1.

24. The method of Claim 1, 2, or 3, wherein said nucleic acid molecule is administered in a dose of from about 75 micrograms to about 1,000 micrograms.

5 25. The method of Claim 1, 2 or 3, wherein said nucleic acid molecule is administered in a dose of not more than about 75 micrograms.

26. The method of Claim 1, 2, or 3, wherein said composition is dehydrated and subsequently rehydrated prior to administration.

10 27. The method of Claim 1, 2, or 3, wherein said composition further comprises an excipient.

100T80 1.22.00.2000

**DECLARATION, PETITION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

(Check one):

- ☐ Declaration Submitted with Initial Filing  
☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID  
IMMUNIZATION OF CATS**

the specification of which (check one):

- ☐ is attached hereto.  
OR  
☒ was filed on 22 October 1999 as PCT International Application Number  
PCT/US99/24769  
☐ and was amended by PCT Article 19 Amendment on \_\_\_\_\_  
(if applicable),  
☐ and was amended by PCT Article 34 Amendment on \_\_\_\_\_  
(if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

## PRIORITY CLAIM

(Check one):

- ☐ no such applications have been filed.
- ☒ such applications have been filed as follows

1) **FOREIGN PRIORITY CLAIM:** I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached	
				Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) **PROVISIONAL PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/105,469	23 October 1998 (23.10.98)
60/122,446	02 March 1999 (02.03.99)

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) **U.S./PCT PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number (if applicable)
	PCT/US99/24769	22 October 1999 (22.10.99)	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

**POWER OF ATTORNEY:**

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. <u>19,162</u>	Peter C. Lauro	Reg. No. <u>32,360</u>
Thomas V. Smurzynski	Reg. No. <u>24,798</u>	DeAnn F. Smith	Reg. No. <u>36,683</u>
Ralph A. Loren	Reg. No. <u>29,325</u>	William D. DeVaul	Reg. No. <u>42,483</u>
Giulio A. DeConti, Jr.	Reg. No. <u>31,503</u>	David J. Rikkers	Reg. No. <u>43,882</u>
Ann Lamport Hammitte	Reg. No. <u>34,858</u>	Chi Suk Kim	Reg. No. <u>42,728</u>
Elizabeth A. Hanley	Reg. No. <u>33,505</u>	Maria Laccotripe Zacharakis	Limited Recognition Under 37 C.F.R. § 10.9(b)
Amy E. Mandragouras	Reg. No. <u>36,207</u>		
Anthony A. Laurentano	Reg. No. <u>38,220</u>	Debra J. Milasincic	Reg. No. <u>46,931</u>
Jane E. Remillard	Reg. No. <u>38,872</u>	David R. Burns	Reg. No. <u>46,590</u>
Jeremiah Lynch	Reg. No. <u>17,425</u>	Sean D. Detweiler	Reg. No. <u>42,482</u>
Kevin J. Canning	Reg. No. <u>35,470</u>	Peter S. Stecher	Reg. No. <u>47,259</u>
Jeanne M. DiGiorgio	Reg. No. <u>41,710</u>	Adam M. Goodman	Reg. No. <u>43,640</u>
Megan E. Williams	Reg. No. <u>43,270</u>	Cynthia L. Kanik	Reg. No. <u>37,320</u>
Nicholas P. Triano III	Reg. No. <u>36,397</u>		

Send Correspondence to:

**Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109,  
United States of America**

Direct Telephone Calls to: (name and telephone number)

**Elizabeth A. Hanley, (617) 227-7400**

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor	
<b>Joel R. HAYNES</b>	
Inventor's signature	Date <u>July 17, 2001</u>
Residence	
<del>611 Hinsdale Ct., Fort Collins, Colorado 80526</del> <u>5455 Mahocker Rd. Mazemanie, WI 53566</u> <b>GRH WI</b>	
Citizenship	
<b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b>Ramani S. WONDERLING</b>	
Inventor's signature <i>Ramani S. Wonderling</i>	Date 7/12/01
Residence 1325 S. WHITE OAK DR., Apt # 1718, Waukegan, IL 60085 (RW) <del>5808 Park Ridge Court, Fort Collins, Colorado 80528</del> (RW) /L	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b>Dan T. STINCHCOMB</b>	
Inventor's signature	Date
Residence <b>8409 South County Road 3, Fort Collins, Colorado 80528</b> (CD)	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

**DECLARATION, PETITION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

(Check one):

- ☐ Declaration Submitted with Initial Filing  
☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID  
IMMUNIZATION OF CATS**

the specification of which (check one):

- ☐ is attached hereto.  
OR  
☒ was filed on 22 October 1999 as PCT International Application Number  
PCT/US99/24769  
☐ and was amended by PCT Article 19 Amendment on \_\_\_\_\_  
(if applicable),  
☐ and was amended by PCT Article 34 Amendment on \_\_\_\_\_  
(if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

## PRIORITY CLAIM

(Check one):

- ☐ no such applications have been filed.
- ☒ such applications have been filed as follows

**1) FOREIGN PRIORITY CLAIM:** I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached	
				Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

**2) PROVISIONAL PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/105,469	23 October 1998 (23.10.98)
60/122,446	02 March 1999 (02.03.99)

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

**3) U.S./PCT PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number (if applicable)
	<b>PCT/US99/24769</b>	<b>22 October 1999 (22.10.99)</b>	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

### POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Peter C. Lauro	Reg. No. 32,360
Thomas V. Smurzynski	Reg. No. 24,798	DeAnn F. Smith	Reg. No. 36,683
Ralph A. Loren	Reg. No. 29,325	William D. DeVaul	Reg. No. 42,483
Giulio A. DeConti, Jr.	Reg. No. 31,503	David J. Rikkers	Reg. No. 43,882
Ann Lamport Hammitte	Reg. No. 34,858	Chi Suk Kim	Reg. No. 42,728
Elizabeth A. Hanley	Reg. No. 33,505	Maria Laccotripe Zacharakis	Limited Recognition Under 37 C.F.R. § 10.9(b)
Amy E. Mandragouras	Reg. No. 36,207		
Anthony A. Laurentano	Reg. No. 38,220	Debra J. Milasincic	Reg. No. 46,931
Jane E. Remillard	Reg. No. 38,872	David R. Burns	Reg. No. 46,590
Jeremiah Lynch	Reg. No. 17,425	Sean D. Detweiler	Reg. No. 42,482
Kevin J. Canning	Reg. No. 35,470	Peter S. Stecher	Reg. No. 47,259
Jeanne M. DiGiorgio	Reg. No. 41,710	Adam M. Goodman	Reg. No. 43,640
Megan E. Williams	Reg. No. 43,270	Cynthia L. Kanik	Reg. No. 37,320
Nicholas P. Triano III	Reg. No. 36,397		

Send Correspondence to:

**Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109,  
United States of America**

Direct Telephone Calls to: (name and telephone number)

**Elizabeth A. Hanley, (617) 227-7400**

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor <b>Joel R. HAYNES</b>	
Inventor's signature	Date
Residence <b>611 Hinsdale Ct., Fort Collins, Colorado 80526</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b><u>Ramani S. WÖNDERLING</u></b>	
Inventor's signature	Date
Residence <b>5808 Park Ridge Court, Fort Collins, Colorado 80528</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b><u>Dan T. STINCHCOMB</u></b>	
Inventor's signature	Date
Residence <b>8409 South County Road 3, Fort Collins, Colorado 80528</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

**DECLARATION, PETITION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

(Check one):

- ☐ Declaration Submitted with Initial Filing  
☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID  
IMMUNIZATION OF CATS**

the specification of which (check one):

- ☐ is attached hereto.

OR

- ☒ was filed on 22 October 1999 as PCT International Application Number  
PCT/US99/24769

- ☐ and was amended by PCT Article 19 Amendment on \_\_\_\_\_  
(if applicable),

- ☐ and was amended by PCT Article 34 Amendment on \_\_\_\_\_  
(if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

## PRIORITY CLAIM

(Check one):

- ☐ no such applications have been filed.
- ☒ such applications have been filed as follows

**1) FOREIGN PRIORITY CLAIM:** I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached	
				Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

**2) PROVISIONAL PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/105,469	23 October 1998 (23.10.98)
60/122,446	02 March 1999 (02.03.99)

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

**3) U.S./PCT PRIORITY CLAIM:** I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number (if applicable)
	<b>PCT/US99/24769</b>	<b>22 October 1999 (22.10.99)</b>	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

### POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Peter C. Lauro	Reg. No. 32,360
Thomas V. Smurzynski	Reg. No. 24,798	DeAnn F. Smith	Reg. No. 36,683
Ralph A. Loren	Reg. No. 29,325	William D. DeVaul	Reg. No. 42,483
Giulio A. DeConti, Jr.	Reg. No. 31,503	David J. Ridders	Reg. No. 43,882
Ann Lamport Hammitte	Reg. No. 34,858	Chi Suk Kim	Reg. No. 42,728
Elizabeth A. Hanley	Reg. No. 33,505	Maria Laccotripe Zacharakis	Limited Recognition Under 37 C.F.R. § 10.9(b)
Amy E. Mandragouras	Reg. No. 36,207	Debra J. Milasincic	Reg. No. 46,931
Anthony A. Laurentano	Reg. No. 38,220	David R. Burns	Reg. No. 46,590
Jane E. Remillard	Reg. No. 38,872	Sean D. Detweiler	Reg. No. 42,482
Jeremiah Lynch	Reg. No. 17,425	Peter S. Stecher	Reg. No. 47,259
Kevin J. Canning	Reg. No. 35,470	Adam M. Goodman	Reg. No. 43,640
Jeanne M. DiGiorgio	Reg. No. 41,710	Cynthia L. Kanik	Reg. No. 37,320
Megan E. Williams	Reg. No. 43,270		
Nicholas P. Triano III	Reg. No. 36,397		

Send Correspondence to:

**Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109,  
United States of America**

Direct Telephone Calls to: (name and telephone number)


**Elizabeth A. Hanley, (617) 227-7400**

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor <b>Joel R. HAYNES</b>	
Inventor's signature	Date
Residence <b>611 Hinsdale Ct., Fort Collins, Colorado 80526</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b>Ramani S. WONDERLING</b>	
Inventor's signature	Date
Residence <b>5808 Park Ridge Court, Fort Collins, Colorado 80528</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

Full name of first inventor <b>Dan T. STINCHCOMB</b>	
Inventor's signature 	Date <b>7/3/01</b>
Residence <b>8409 South County Road 3, Fort Collins, Colorado 80528</b>	
Citizenship <b>United States of America</b>	
Post Office Address (if different)	

2001-07-03 14:29:00